Atogepant

Introduction Overview

Generic Name

Atogepant

Brand Name

Qulipta

Dosage Form

Oral tablets (10 mg, 30 mg, 60 mg)

Drug Class

Calcitonin gene-related peptide (CGRP) receptor antagonist

Pharmacokinetics

Absorption

Atogepant is administered orally and displays good bioavailability with peak plasma concentrations typically achieved within 2 hours post-dose. The drug can be taken with or without food, and food does not significantly impact its absorption. Its pharmacokinetic profile supports once daily dosing, allowing for steady therapeutic levels in plasma, which is advantageous for migraine prophylaxis.

Distribution

After absorption, atogepant is moderately distributed throughout the body. The volume of distribution indicates distribution primarily into systemic circulation with limited penetration into certain tissues, including the central nervous system. Atogepant is highly bound to plasma proteins, which influences its free drug concentration and the potential for drug interactions.

Metabolism

Atogepant undergoes hepatic metabolism predominantly via the cytochrome P450 enzyme CYP3A4, with minor contributions from other pathways. This metabolism results in several inactive metabolites. Given its reliance on CYP3A4, concomitant administration with inhibitors or inducers of this enzyme can significantly affect atogepant plasma concentrations.

Elimination

The elimination of atogepant occurs mainly via fecal excretion, with a smaller proportion eliminated renally. The elimination half-life ranges approximately between 10 to 12 hours, supporting once daily dosing. Renal or hepatic impairment may affect its clearance; dose modifications may be necessary in these populations. The drug's elimination profile aids in maintaining steady-state exposure without accumulation.

Dosage Forms

Adults

Atogepant is available as oral tablets in strengths of 10 mg, 30 mg, and 60 mg, intended for once-daily administration for the preventive treatment of migraine in adults. For episodic migraine prophylaxis, dosing options include 10 mg, 30 mg, or 60 mg once daily. For chronic migraine prophylaxis, the recommended dose is 60 mg once daily.

Adolescents

Atogepant is currently FDA-approved only for use in adults; safety and efficacy in pediatric and adolescent populations have not been established. Therefore, it is not recommended for use in patients under 18 years of age.

Special Populations

In patients with moderate to severe hepatic impairment or those undergoing dialysis with kidney disease, caution is advised due to altered pharmacokinetics. Dose adjustments or avoidance may be necessary. Additionally, dose modification is recommended when administered with strong CYP3A4 inhibitors or inducers, or OATP inhibitors, due to potential changes in drug exposure.

Mechanism Of Action

Atogepant exerts its pharmacological effect by selectively and competitively antagonizing the calcitonin gene-related peptide (CGRP) receptor. CGRP is a neuropeptide involved in migraine pathophysiology, where it promotes vasodilation, neurogenic inflammation, and transmission of pain signals within the trigeminovascular system. By blocking CGRP receptors, atogepant prevents CGRP from binding and activating these receptors, thereby inhibiting these migraine-promoting processes.

On a molecular level, atogepant binds the CGRP receptor, which is a G protein-coupled receptor composed of multiple subunits. The blockade interferes with receptor activation and downstream intracellular signaling cascades that lead to vasodilation and release of inflammatory mediators. This inhibition reduces neuronal excitability and limits the cascade that leads to migraine headache initiation.

Clinically, this mechanism translates to a reduction in the frequency, severity, and duration of migraine attacks when administered prophylactically. Atogepant's oral administration and receptor selectivity differentiate it from monoclonal antibody CGRP antagonists, offering a convenient small-molecule option for preventive migraine therapy.

Research studies, including randomized controlled trials, have demonstrated that by inhibiting CGRP receptor activity, atogepant effectively decreases migraine days per month and improves patient quality of life compared to placebo.

Pharmacological Actions

Selective antagonism of CGRP receptors in the central and peripheral nervous system
Prevention of CGRP-mediated vasodilation leading to reduced neurogenic inflammation
Inhibition of pain signal transmission in the trigeminovascular system
Reduction in frequency and severity of migraine headache episodes
Once-daily oral administration provides sustained receptor blockade
Minimal central nervous system penetration reduces sedation risk
Does not cause vasoconstriction, making it safer than triptans for patients with cardiovascular risk
Potential modulation of sensory neuron excitability contributing to analgesic effects
Limited drug interactions due to selective metabolic pathways
Non-immunogenic small molecule, unlike monoclonal antibody CGRP inhibitors

Therapeutic Clinical Uses

Preventive treatment of episodic migraine in adults
Preventive treatment of chronic migraine in adults
Reduction of migraine frequency and associated symptoms
Management of migraine in patients who cannot tolerate or respond to other preventive therapies
Use in patients seeking oral migraine prophylactic medication
Adjunctive therapy to acute migraine treatments for overall migraine burden reduction
Improvement in quality of life and functional ability associated with migraine prevention
Potential therapeutic option for migraine patients with contraindications to vasoconstrictors

Side Or Adverse Effects

Nausea, which may be transient and manageable
Constipation as a common gastrointestinal side effect
Fatigue or feeling tired reported in some patients
Weight loss observed in certain cases
Potential for allergic reactions including rash, swelling, or difficulty breathing
Rare hypersensitivity reactions warranting immediate medical attention
No reported hair loss in clinical trials, though anecdotal reports exist for CGRP inhibitors generally
Headache or dizziness reported infrequently
No significant cardiovascular adverse events observed in clinical studies
Generally well tolerated with low incidence of serious adverse effects
Potential hepatic enzyme elevations requiring monitoring in some patients

Precautions

Use cautiously in patients with a history of liver disease due to hepatic metabolism
Careful use advised in patients with renal impairment or on dialysis
Monitor for signs of allergic reactions or hypersensitivity
Adjust dose or avoid concomitant use with strong CYP3A4 inhibitors, inducers, or OATP inhibitors
Not studied or approved for use in pediatric populations — avoid in under 18 years old
Pregnant women should use only if potential benefits justify potential risks; animal studies show fetal harm
Uncertain passage into breast milk; consult healthcare provider before use during breastfeeding
Advise patients on consistent daily dosing and management of missed doses
Inform patients about potential gastrointestinal side effects and management strategies
Avoid use in patients with known hypersensitivity to atogepant or any formulation excipients

Warnings

Hypersensitivity reactions including urticaria, angioedema, or anaphylaxis can occur
Do not use in individuals allergic to atogepant or its inactive ingredients
Use only as directed by healthcare provider to avoid adverse effects or suboptimal dosing
Potential drug interactions with medications metabolized by CYP3A4 should be carefully managed
Risk-benefit assessment required in pregnant patients due to animal data suggesting fetal risk
Avoid use in combination with other CGRP antagonists due to unknown safety profile
Not suitable for treatment of acute migraine attacks; intended only for prophylactic use
Patients should report any unusual symptoms promptly to healthcare providers
Monitor hepatic function periodically in patients with preexisting liver disease or those on interacting drugs
Safety and efficacy in patients under 18 years or with severe renal impairment remain unestablished

Contraindications

Known hypersensitivity or allergy to atogepant or any component of its formulation
Concomitant use with other CGRP receptor antagonists due to lack of safety data
Patients with severe hepatic impairment unless benefits outweigh risks and under close monitoring
Use in pediatric patients under 18 years old due to unknown safety and efficacy
Hypersensitivity reactions to excipients such as colloidal silicon dioxide or sodium stearyl fumarate
Avoid use during breastfeeding unless clearly needed and advised by healthcare provider
Patients with known rare hereditary problems of galactose intolerance or Lapp lactase deficiency (if liquid formulations were available - not applicable here)

Drug Interactions

Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, clarithromycin) may increase atogepant plasma levels requiring dose adjustment or avoidance
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can reduce atogepant effectiveness due to decreased plasma concentrations
Use with OATP inhibitors (e.g., cyclosporine) may increase systemic exposure to atogepant
Herbal supplements such as St. John's wort can induce CYP3A4 and reduce atogepant effectiveness
Antiviral drugs for HIV treatment (e.g., efavirenz, etravirine) impact CYP3A4 activity influencing atogepant levels
Caution with seizure medications (carbamazepine, phenytoin) as they can alter metabolism
Potential for interaction with other drugs metabolized by CYP3A4 necessitates medication review
No significant interactions reported with common analgesics but comprehensive clinical data is limited
Concomitant use with other migraine preventive agents requires clinical judgment
Patient medication lists must be reviewed thoroughly to avoid unrecognized interactions

Preparations Of The Drug

Oral tablets containing atogepant in strengths of 10 mg, 30 mg, and 60 mg
Film-coated tablets for ease of swallowing and stability
Distributed under the brand name Qulipta manufactured by Forest Laboratories Ireland Ltd for AbbVie Inc.
Tablets contain inactive ingredients such as colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate
Packaging designed for once daily dosing with standard blister packs
No current liquid or injectable formulations available
Pack sizes vary depending on prescription requirements
Tablets formulated for stable storage between 15°C and 30°C (59°F to 86°F)
No over-the-counter preparations; available by prescription only
No generic versions currently available, brand name product only